PHARMARON BEIJING CO., LTD. Pharmaron Beijing Co., Ltd. Share Price Hong Kong S.E.
Equities
3759
CNE100003PG4
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.83 HKD | +2.50% |
|
-4.00% | -37.86% |
| Sales 2024 * | 12.65B 1.75B 13.66B 146B | Sales 2025 * | 15.24B 2.1B 16.45B 176B | Capitalization | 33.27B 4.59B 35.92B 383B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.61B 223M 1.74B 18.57B | Net income 2025 * | 2.16B 298M 2.33B 24.88B | EV / Sales 2024 * | 2.89 x |
| Net Debt 2024 * | 3.36B 464M 3.63B 38.69B | Net Debt 2025 * | 3.14B 433M 3.39B 36.12B | EV / Sales 2025 * | 2.39 x |
| P/E ratio 2024 * |
21
x | P/E ratio 2025 * |
17.5
x | Employees | - |
| Yield 2024 * |
1.04% | Yield 2025 * |
1.39% | Free-Float | 47.74% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +2.50% | ||
| 1 week | -4.00% | ||
| 1 month | +1.24% | ||
| 3 months | -6.02% | ||
| 6 months | -46.86% | ||
| Current year | -37.86% |
1 week
9.50
10.44
1 month
9.5012.02
Current year
8.2516.10
1 year
8.2523.40
3 years
8.2594.22
5 years
8.2594.22
10 years
8.2594.22
| Managers | Title | Age | Since |
|---|---|---|---|
Xiao Qiang Lou
FOU | Founder | 55 | 01/04/01 |
Bei Zheng
FOU | Founder | 57 | 01/04/01 |
Bo Liang Lou
CEO | Chief Executive Officer | 60 | 01/04/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Kwan Hung Tsang
BRD | Director/Board Member | 60 | 15/19/15 |
Bo Liang Lou
CEO | Chief Executive Officer | 60 | 01/04/01 |
Xiao Qiang Lou
FOU | Founder | 55 | 01/04/01 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.55% | 4 M€ | -27.92% | ||
| 0.57% | 2 M€ | -18.79% | - | |
| 0.26% | 3 M€ | +0.10% | - | |
| 0.09% | 2 M€ | -.--% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/24/31 | 9.83 | +2.50% | 6,235,773 |
| 30/24/30 | 9.59 | -2.34% | 3,988,703 |
| 29/24/29 | 9.82 | -1.70% | 2,615,884 |
| 28/24/28 | 9.99 | -0.70% | 2,346,500 |
| 27/24/27 | 10.06 | -1.76% | 4,732,125 |
Delayed Quote Hong Kong S.E., May 31, 2024 at 01:38 pm IST
More quotes
Pharmaron Beijing Co. is specialised in the research, development and manufacturing of small molecule drugs, cell therapies and gene therapies. Net sales break down by activity as follows:
- laboratory services (61.3%);
- development and production of chemical processes and formulations (23.5%);
- clinical research services (12.8%);
- other (2.4%);
Net sales are distributed geographically as follows: China (17.1%), Asia (2.6%), North America (64.2%), Europe (15.6%) and other (0.5%).
Calendar
06/06/2024
- Annual General Meeting
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
20
Last Close Price
20.64
CNY
Average target price
24.15
CNY
Spread / Average Target
+16.99%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +43.36% | 54.63B | |
| -5.31% | 39.92B | |
| +14.75% | 26.86B | |
| -12.56% | 26.22B | |
| -22.45% | 18.78B | |
| +25.12% | 12.21B | |
| +0.04% | 12.16B | |
| +26.04% | 11.94B | |
| -11.83% | 10.74B |
- Stock Market
- Equities
- 300759 Stock
- 3759 Stock
